Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference

Rhea-AI Summary

Biora Therapeutics (Nasdaq: BIOR), a biotech company focused on reimagining therapeutic delivery, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event is scheduled for August 13-15, 2024, in Boston, MA.

Key details of Biora's participation include:

• Company presentation on Tuesday, August 13, 2024, at 2:30 PM Eastern time
• One-on-one investor meetings
• Live webcast available at https://wsw.com/webcast/canaccord98/bior/2458676
• Replay of the presentation will be accessible on Biora's website after the conference

This participation provides an opportunity for Biora to showcase its innovations in therapeutic delivery to potential investors and industry professionals.

SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate in the Canaccord Genuity 44^th Annual Growth Conference, August 13–15, 2024.

Canaccord Genuity 44^th Annual Growth Conference, Boston, MA
Company presentation and 1x1 investor meetings        

Date:	Tuesday, August 13, 2024
Time:	2:30 PM Eastern time
Live Webcast:	https://wsw.com/webcast/canaccord98/bior/2458676

A replay will also be available on Biora’s website following the conference.

About Biora Therapeutics
Biora Therapeutics is a clinical-stage biotech developing two smart pill-based therapeutics platforms: the NaviCap™ platform for colon-targeted treatment of IBD, designed to improve patient outcomes through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ platform for oral delivery of large molecules, designed to replace injection with needle-free, oral delivery for better management of chronic diseases.

For more information, visit bioratherapeutics.com or follow the company on LinkedIn or X.

Safe Harbor Statement or Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development, preclinical and clinical trial activities, including those involving BT-600 and our NaviCap platform and model projections, and partnering and collaboration efforts with third parties, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “envision,” “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “anticipate,” “forward,” “believe,” “design,” “estimate,” “predict,” “projects,” “projecting,” “potential,” “plan,” “goal(s),” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future FDA filings and initiate and execute clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators or partners, our ability to raise sufficient capital to achieve our business objectives, our ability to maintain our listing on the Nasdaq Global Market, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) and other subsequent documents, including Quarterly Reports on Form 10-Q, that we file with the SEC.

Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
IR@bioratherapeutics.com
(646) 627-8390

Media Contact
Liz Robinson
CG Life
lrobinson@cglife.com

FAQ

When is Biora Therapeutics (BIOR) presenting at the Canaccord Genuity Growth Conference?

Biora Therapeutics (BIOR) is presenting at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024, at 2:30 PM Eastern time.

Where can I watch the live webcast of Biora Therapeutics' (BIOR) presentation?

The live webcast of Biora Therapeutics' (BIOR) presentation can be accessed at https://wsw.com/webcast/canaccord98/bior/2458676.

Will there be a replay available of Biora Therapeutics' (BIOR) conference presentation?

Yes, a replay of Biora Therapeutics' (BIOR) presentation will be available on the company's website following the conference.

What type of meetings will Biora Therapeutics (BIOR) be conducting at the Canaccord Genuity conference?

Biora Therapeutics (BIOR) will be conducting one-on-one investor meetings at the Canaccord Genuity 44th Annual Growth Conference.

What is the focus of Biora Therapeutics (BIOR) as mentioned in the press release?

Biora Therapeutics (BIOR) is described as a biotech company reimagining therapeutic delivery.